A practical reference on Toll-like receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Moore KL (2003). "The biology and enzymology of protein tyrosine O-sulfation". J. Biol. Chem. 278 (27): 24243–6. doi:10.1074/jbc.R300008200. PMID 12730193. Hoffhines AJ; Damoc, E; Bridges, KG; Leary, JA; Moore, KL (2006). "Detection and purification of tyrosine-sulfated proteins using a novel anti-sulfotyrosine monoclonal antibody". J. Biol. Chem. 281 (49): 37877–87. doi:10.1074/jbc.M609398200. PMC 1764208. PMID 17046811.
In a settlement approved by the Federal Court in 2022, 7-Eleven agreed to pay $98 million to franchisees alleging that they were misled regarding store profitability. Though the settlement was reached without any admission of fault, the case included allegations that 7-Eleven had misrepresented employee-related costs as about seven percent of total costs, when a more accurate figure was around thirteen percent. This difference made many franchisees "unable to make a profit unless they underpaid staff", as was shown in the wage theft class action.
At the end of the 1950s, the USSR constructed the first satellite—Sputnik 1, which marked the beginning of the Space Race—a competition to achieve superior spaceflight capability with the United States. This was followed by other successful satellites, most notably Sputnik 5, where test dogs were sent to space. On 12 April 1961, the USSR launched Vostok 1, which carried Yuri Gagarin, making him the first human to ever be launched into space and complete a space journey. The first plans for space shuttles and orbital stations were drawn up in Soviet design offices, but personal disputes between designers and management prevented their development. In terms of the Luna program, the USSR only had automated spacecraft launches with no crewed spacecraft. The N1—a Super heavy-lift launch vehicle intended to match the American Saturn V for a Soviet crewed moon landing—failed all four of its test launches, and the 'Moon' part of Space Race was won by the Americans. The Soviet public's reaction to the American moon-landing was mixed. The Soviet government limited the release of information about it, which affected the reaction. A portion of the populace did not give it attention, and another portion was angered. In the 1970s, specific proposals for the design of a space shuttle emerged, but shortcomings, especially in the electronics industry (rapid overheating of electronics), postponed it till the end of the 1980s. The first shuttle, the Buran, flew in 1988, but without a human crew. Another, Ptichka, endured prolonged construction and was canceled in 1991.
The spray is a combination of local anaesthetics lidocaine and prilocaine in a metered-dose aerosol that is sprayed directly on the penis to numb sensations. It was developed by the same group that invented the erectile dysfunction drug sildenafil. The drug was approved in Europe and was released in the UK market in November 2016 and within the EU will be marketed by, early in 2017 In the United States, the Food and Drug Administration (FDA) is expected to approve the drug in 2018.
Sources: en.wikipedia.org
==== Bailout regulator ==== The emergency breathing gas from the bailout cylinder passes through a conventional scuba first stage regulator at the cylinder valve, via a low-pressure hose, to the bailout block, where it is normally isolated by the bailout valve. When the diver needs to switch over to bailout gas they simply open the bailout valve and the gas is supplied to the helmet or mask. As the valve is normally closed, a leak in the first stage regulator seat will cause the interstage pressure to rise, and unless an overpressure relief valve is fitted to the first stage the hose may burst. Aftermarket overpressure valves are available which can be fitted into a standard low-pressure port of most first stages. If the interstage pressure for the bailout regulator is lower than the main supply pressure, the main supply will override the bailout gas, and continue to flow. This can be a problem if the diver switches to bailout because the main supply is contaminated. If, on the other hand, bailout pressure is higher than main supply pressure, the bailout gas will override the main gas supply if the valve is opened. This will result in the bailout gas being used up if the valve leaks. The diver should periodically check that bailout cylinder pressure is still sufficient for the rest of the dive, and abort the dive if it is not. For this reason the bailout regulator must be fitted with a submersible pressure gauge to which the diver can refer to check the pressure.
=== Movement of NAPLs in the saturated zone === In the saturated zone, the spaces between particles are filled with water. As such, a three-phase model of NAPL phase distribution is used in this zone, which excludes the gaseous phase. Once NAPLs reach the water table in the saturated zone, LNAPLs will float while DNAPLs will sink. Both LNAPLs and DNAPLs can remain in the water table for long periods of time, slowly dissolving and forming harmful chemical plumes; for this reason, remediation in the saturated zone is of particular importance to scientists.
Several efforts to develop standards in the NGS field have been attempted to address these challenges, most of which have been small-scale efforts arising from individual labs. Most recently, a large, organized, FDA-funded effort has culminated in the BioCompute standard. On 26 October 1990, Roger Tsien, Pepi Ross, Margaret Fahnestock and Allan J Johnston filed a patent describing stepwise ("base-by-base") sequencing with removable 3' blockers on DNA arrays (blots and single DNA molecules). In 1996, Pål Nyrén and his student Mostafa Ronaghi at the Royal Institute of Technology in Stockholm published their method of pyrosequencing. On 1 April 1997, Pascal Mayer and Laurent Farinelli submitted patents describing DNA colony sequencing. The DNA sample preparation and random surface-polymerase chain reaction (PCR) arraying methods described in this patent, coupled to Roger Tsien et al.'s "base-by-base" sequencing method, is now implemented in Illumina's Hi-Seq genome sequencers. In 1998, Phil Green and Brent Ewing of the University of Washington described their phred quality score for sequencer data analysis, a landmark analysis technique that gained widespread adoption, and which is still the most common metric for assessing the accuracy of a sequencing platform. Lynx Therapeutics published and marketed massively parallel signature sequencing (MPSS), in 2000.
=== Activity === This enzyme participates in 8 metabolic pathways: alanine and aspartate metabolism, methionine metabolism, valine, leucine and isoleucine degradation, tyrosine metabolism, phenylalanine metabolism, tryptophan metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, and alkaloid biosynthesis. It employs one cofactor, flavin adenine dinucleotide (FAD). The enzyme binds to FAD in the first step of the catalytic process, thereby reducing FAD to FADH2. The FAD is regenerated from FADH2 by oxidation as a result of O2 being reduced to H2O2. The mechanism proceeds via oxidative deamination of the L-amino acid, which affords an imino acid intermediate. Following hydrolysis of the intermediate, the enzyme successfully affords the 2-oxo acid, as shown in Scheme 1.
In December, 2020, Sinclair's group published that three Yamanaka transcription factors, Oct4, Sox2, and Klf4, when delivered together in a virus, could safely reverse the age of human and mouse cells, and restore the vision of old mice and mice with glaucoma. In 2023, with Bruce Ksander's lab at Mass Eye and Ear, they presented a poster at the annual ARVO conference accompanied by a company press release claiming that vision could be restored in non-human primates. In January 2023, Sinclair's lab published research in Cell purporting to support his Information Theory of Aging, the idea that mammalian aging is due to the loss of epigenetic information, and that Yamanaka factors could exert a degree of artificial control over senescence and rejuvenation in mice. The paper received a formal reply pointing out that the treatment used in the paper is known to produce p53-dependent cell death in a 30-day period in which the mice were not observed. Sinclair's claims of reverse aging have received criticism from other scientists.
Sources: en.wikipedia.org
== Solubility == Another property of nanoparticles that is heavily influenced by the surfactants is the solubility of the nanoparticle. One can imagine that a metallic nanoparticle would not dissolve well in organic solvents. By adding the surfactants the nanoparticles will stay more evenly dispersed throughout the solvent. This is due to the, often, amphiphilic nature of the surfactants. The interfacial layer can be used to essentially tune the solubility of nanoparticles in different media, which can range from extremely hydrophilic to hydrophobic.
A story with Frazier Tharpe for GQ, published on June 2, 2025, started by stating that Clipse were unimpressed with the current state of mainstream hip-hop. The brothers gave Stove God Cooks and Future as exceptions. Pusha T lamented the feelings of loneliness and need to play "industry games" that came with his solo career, revealed that he was already becoming disillusioned with his former boss West during the 2019 recording sessions for Jesus Is King, and criticized West for his perceived character flaws. He also denied being a bad friend to West. The story of Clipse's dispute with Def Jam Recordings was told for the first time in this interview. Also included were comments about Drake suing Universal Music Group ("The suing thing is bigger than some rap shit. I just don't rate you.") and more details about the album: tracks "Mike Tyson", "POV", "F.I.C.O.", and features from Stove God Cooks and Lamar. After the release of "So Be It", GQ published a follow-up article (with unused excerpts from the interview) in which the song was discussed, including lyrics from Pusha T which diss Travis Scott. Another interview with Andre Gee for Rolling Stone was published on June 9. Clipse elaborated on their distribution deal with Roc Nation and announced a nationwide United States tour, planned to take place across twenty-five shows from August 3 to September 10.
== External links == Escape From City 17 – Part One at IMDb Escape From City 17 – Part Two at IMDb Escape from City 17 – Part One on YouTube Escape from City 17 – Part Two on YouTube Escape from City 17 – Part Two on Vimeo Escape from City 17 – Part Three Teaser on Vimeo Escape from City 17 at AFI Digifest 2009 – interview on YouTube
== External links == Biological Products at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Debbie Strickland (2007). "Guide to Biotechnology" (PDF). Biotechnology Industry Organization (BIO). Archived from the original (PDF) on 2007-09-27. Retrieved 2007-12-17. Timothy B. Coan; Ron Ellis (2001-06-01). "Report for USA Specialty Pharmaceuticals: Generic Biologics: The Next Frontier" (PDF). Consumer Project on Technology. Retrieved 2007-12-17. "About biologics". National Psoriasis Foundation. 2006-11-01. Archived from the original on 2006-01-01. Retrieved 2007-12-17.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.